| P50 | author | Rivka Inzelberg | Q56613383 |
| P2093 | author name string | Eitan Friedman | |
| | Esther Azizi | |
| | Shira Flash | |
| P2860 | cites work | A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism. | Q48369707 |
| | The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma | Q50459034 |
| | Red hair is the null phenotype of MC1R. | Q50649084 |
| | The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. | Q53666273 |
| | High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL | Q56437244 |
| | Malignant Melanoma and Other Types of Cancer Preceding Parkinson Disease | Q58006630 |
| | Lack of association betweenMC1Rvariants and Parkinson disease in European descent | Q58200083 |
| | Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee | Q21092426 |
| | Caffeine interaction with glutamate receptor gene GRIN2A: Parkinson's disease in Swedish population | Q21559457 |
| | Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans | Q24312946 |
| | Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling | Q24313304 |
| | The associations between Parkinson's disease and cancer: the plot thickens | Q26778641 |
| | The genetics and neuropathology of Parkinson's disease | Q26859945 |
| | Alpha-synuclein in Lewy bodies | Q27860680 |
| | Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance | Q28077356 |
| | The EIF4G1 gene and Parkinson's disease | Q28116373 |
| | Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on α-synuclein | Q28117589 |
| | Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease | Q28244731 |
| | Neuroprotective actions of melanocortins: a therapeutic opportunity | Q28283714 |
| | A protein deep sequencing evaluation of metastatic melanoma tissues | Q28546229 |
| | Parkin Somatic Mutations Link Melanoma and Parkinson's Disease | Q30389245 |
| | The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker | Q40298762 |
| | Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma | Q40687265 |
| | Association Between Parkinson Disease and Risk of Cancer in Taiwan. | Q40729085 |
| | LRRK2 in Transcription and Translation Regulation: Relevance for Parkinson's Disease | Q41009946 |
| | The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. | Q41512301 |
| | The tumor suppressor PTEN regulates motor responses to striatal dopamine in normal and Parkinsonian animals | Q41523757 |
| | Rare variants in MC1R/TUBB3 exon 1 are not associated with Parkinson's disease | Q42575125 |
| | Associations Between Parkinson Disease and Cancer in US Asian Americans | Q43432326 |
| | Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies | Q43495919 |
| | Parkinson disease and malignant melanoma in first-degree relatives of patients with early-onset melanoma | Q43960530 |
| | MC1R variant alleles and malignant melanoma risk in Israel. | Q46002878 |
| | The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. | Q46027013 |
| | Neurochemical characterization of dopaminergic neurons in human striatum | Q46560302 |
| | Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease | Q46593989 |
| | 100 years of Lewy pathology | Q48278741 |
| | Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma | Q33576922 |
| | Catalytic Function of PLA2G6 Is Impaired by Mutations Associated with Infantile Neuroaxonal Dystrophy but Not Dystonia-Parkinsonism | Q33707768 |
| | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation | Q34051230 |
| | LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease | Q34299954 |
| | Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assay | Q34379982 |
| | Genetics of Parkinson's disease--state of the art, 2013. | Q34386801 |
| | The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells | Q34428287 |
| | Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas | Q34533693 |
| | Glutamate receptor gene GRIN2A, coffee, and Parkinson disease | Q34549411 |
| | Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease | Q34549562 |
| | Characterization of PLA2G6 as a locus for dystonia-parkinsonism | Q34593410 |
| | Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins | Q34610662 |
| | New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment. | Q34626994 |
| | The many faces of α-synuclein: from structure and toxicity to therapeutic target | Q34972009 |
| | Meta-analysis of the relationship between Parkinson disease and melanoma | Q35049770 |
| | Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice | Q35113222 |
| | Exome sequencing identifies GRIN2A as frequently mutated in melanoma | Q35179796 |
| | Risk prediction models for melanoma: a systematic review | Q35181221 |
| | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis | Q35195815 |
| | Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial | Q35221729 |
| | DJ1 represses glycolysis and cell proliferation by transcriptionally up-regulating Pink1. | Q35269486 |
| | The link between Parkinson's disease and breast and prostate cancers: A meta-analysis | Q35410531 |
| | Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer | Q35545780 |
| | No association between Parkinson disease alleles and the risk of melanoma | Q35661342 |
| | Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study | Q35674748 |
| | Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease | Q35834043 |
| | Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study | Q35897974 |
| | Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma | Q36019187 |
| | The association between Parkinson's disease and melanoma: a systematic review and meta-analysis | Q36243422 |
| | Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families | Q36301055 |
| | SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex | Q36378135 |
| | Impairment of PARK14-dependent Ca(2+) signalling is a novel determinant of Parkinson's disease | Q36511361 |
| | Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites | Q36534162 |
| | Is the MC1R variant p.R160W associated with Parkinson's? | Q36535790 |
| | Atypical cancer pattern in patients with Parkinson's disease. | Q36615809 |
| | Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease | Q36796504 |
| | Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease | Q36841500 |
| | Are Parkinson disease patients protected from some but not all cancers? | Q36910705 |
| | The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease | Q37054679 |
| | The Evolution of Genetics: Alzheimer's and Parkinson's Diseases | Q37074331 |
| | Genetic determinants of hair color and Parkinson's disease risk | Q37091302 |
| | Germline MC1R status influences somatic mutation burden in melanoma. | Q37096447 |
| | Whole-Exome Sequencing in Familial Parkinson Disease | Q37098159 |
| | Tumorigenesis and neurodegeneration: two sides of the same coin? | Q37214823 |
| | Family history of melanoma and Parkinson disease risk | Q37393477 |
| | Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. | Q37395786 |
| | The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. | Q37605589 |
| | LRRK2 in Parkinson's disease: function in cells and neurodegeneration | Q37608630 |
| | Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease | Q37652816 |
| | Parkinson's disease and cancer risk: a systematic review and meta-analysis | Q37669823 |
| | Common pathogenic pathways in melanoma and Parkinson disease | Q37805957 |
| | The association between Parkinson's disease and melanoma | Q37826159 |
| | The genetics of melanoma: recent advances | Q38123223 |
| | Oncogenes in melanoma: an update | Q38182239 |
| | MC1R and NR4A receptors in cellular stress and DNA repair: implications for UVR protection | Q38206554 |
| | Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma | Q38210674 |
| | LRRK2 pathobiology in Parkinson's disease | Q38253871 |
| | Genetic movement disorders in patients of Jewish ancestry | Q38262951 |
| | Functions and characteristics of PINK1 and Parkin in cancer | Q38305415 |
| | Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. | Q38363823 |
| | Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. | Q38520438 |
| | The genomic landscape of cutaneous melanoma | Q38718904 |
| | Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces | Q38834595 |
| | Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies | Q39009613 |
| | Genome-wide associations studies for melanoma and nevi | Q39695435 |
| | Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. | Q39838070 |
| | Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma | Q40200165 |
| | Genetic analysis of MC1R variants in Chinese Han patients with sporadic Parkinson's disease. | Q40251511 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 811-820 | |
| P577 | publication date | 2016-10-19 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Cutaneous malignant melanoma and Parkinson disease: Common pathways? | |
| P478 | volume | 80 | |